BioVaxys Trading Halted Amid Filing Delay
PremiumCompany AnnouncementsBioVaxys Trading Halted Amid Filing Delay
2M ago
BioVaxys Secures Funding for Immunotherapy Advancement
PremiumCompany Announcements
BioVaxys Secures Funding for Immunotherapy Advancement
3M ago
BioVaxys Secures Funding for Immunotherapy Growth
PremiumCompany Announcements
BioVaxys Secures Funding for Immunotherapy Growth
3M ago
BioVaxys Delays Financial Filings, Aims for Compliance
PremiumCompany AnnouncementsBioVaxys Delays Financial Filings, Aims for Compliance
4M ago
BioVaxys Gains U.S. Patent, Advances Global Filings
PremiumCompany Announcements
BioVaxys Gains U.S. Patent, Advances Global Filings
4M ago
BioVaxys Plans Capital Boost with Private Placement
PremiumCompany Announcements
BioVaxys Plans Capital Boost with Private Placement
4M ago
BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC.
PremiumPress ReleasesBIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC.
5M ago
BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC.
PremiumPress Releases
BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC.
5M ago
BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.
PremiumPress Releases
BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100